Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Khiron Life Sciences Corp KHRWF


Primary Symbol: V.KHRN.H Alternate Symbol(s):  V.KHRN.WT.H | KHRNF

Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line... see more

TSXV:KHRN.H - Post Discussion

Khiron Life Sciences Corp > medical cannabis prescription growth South America/Europe
View:
Post by Betteryear2 on Oct 04, 2021 6:40am

medical cannabis prescription growth South America/Europe

TORONTOOct. 4, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated international cannabis leader with core operations in Latin America and Europe, is pleased to provide a corporate update on global medical cannabis operations:

Medical Cannabis

Latin America

  • Medical cannabis prescriptions grew by more than 40%, from Q2 2021
  • Year to date medical cannabis prescriptions have exceeded 35,000 units, 600% more than the entire 2020 fiscal year
  • Total medical cannabis patients in Q3 increased to more than 9,600, up 32% from Q2 2021
  • 62% of the patients in Q3 were returning patients, up 35% from Q2 2021
  • 47% of units sold were covered by insurance
  • New satellite clinics accounted for 10% of prescriptions

Europe

  • Europe generated 30% of the Company's medical cannabis sales in Q3 2021
  • Germany revenues expected to grow more than 80% and UK revenues expected to grow more than 70% quarter on quarter
  • The Company has increased its imported volumes in the U.K., ensuring uninterrupted supply for all Khiron patients

Health Services

  • Year to date patient visits at Khiron clinics have exceeded 104,000, topping all patient visits in 2020
  • Revenue in health services is steadily returning to normal at Zerenia clinics as pandemic measures ease
  • Total quarterly patient visits at Zerenia were up 18% quarter on quarter
  • Khiron will expand its flagship clinic brand, Zerenia to the UK, with the first Zerenia opening in London in Q4 2021.

Management Commentary
"Through the end of Q3, the Company continued to make steady progress in helping more patients access medical cannabis. Europe is starting to become an important market for the Company, and we will soon be opening our first Zerenia medical cannabis clinic in the UK.  Our integrated clinic model continues to connect patients, doctors, and insurance, helping improve patient outcomes.  The integrated medical clinic approach offers a range of treatments and services, including medical cannabis, that help patients save time and money by not having to travel to seek out individual treatments.   Almost half of our patients have insurance coverage now, a tremendous improvement since our first covered prescription in December of 2020. ", commented Alvaro Torres, Chief Executive Officer and Director of the Company.

https://www.prnewswire.com/news-releases/khiron-reports-medical-cannabis-prescription-growth-in-south-america-and-europe-301391489.html

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities